Cargando…

Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study

Background: We developed a hybrid platform using a negative combined with a positive selection strategy to capture circulating tumor cells (CTCs) and detect epidermal growth factor receptor (EGFR) mutations in patients with metastatic lung adenocarcinoma. Methods: Blood samples were collected from p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shih-Hong, Wu, Min-Hsien, Wang, Hung-Ming, Hsu, Ping-Chih, Fang, Yueh-Fu, Wang, Chih-Liang, Chu, Hui-Chun, Lin, Hung-Chih, Lee, Li-Yu, Wu, Ching-Yang, Yang, Cheng-Ta, Chen, Jen-Shi, Hsieh, Jason Chia-Hsun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505961/ https://www.ncbi.nlm.nih.gov/pubmed/36142574 http://dx.doi.org/10.3390/ijms231810661

Ejemplares similares

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

The Factors Predicting Concordant Epidermal Growth Factor Receptor (EGFR) Mutation Detected in Liquid/Tissue Biopsy and the Related Clinical Outcomes in Patients of Advanced Lung Adenocarcinoma with EGFR Mutations
por: Kuo, Chia-Yu, et al.
Publicado: (2019)

A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
por: Wang, Chin-Chou, et al.
Publicado: (2021)

Levels of Circulating Microparticles in Lung Cancer Patients and Possible Prognostic Value
por: Tseng, Chia-Cheng, et al.
Publicado: (2013)

Combined analysis of circulating epithelial cells and serum thyroglobulin for distinguishing disease status of the patients with papillary thyroid carcinoma
por: Lin, Hung-Chih, et al.
Publicado: (2015)

A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer
por: Chou, Wen-Chi, et al.
Publicado: (2018)

The Prognostic Roles of Pretreatment Circulating Tumor Cells, Circulating Cancer Stem-Like Cells, and Programmed Cell Death-1 Expression on Peripheral Lymphocytes in Patients with Initially Unresectable, Recurrent or Metastatic Head and Neck Cancer: An Exploratory Study of Three Biomarkers in One-time Blood Drawing
por: Chang, Pei-Hung, et al.
Publicado: (2019)

Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma
por: Lin, Chun-Yu, et al.
Publicado: (2017)

Circulating p16-Positive and p16-Negative Tumor Cells Serve as Independent Prognostic Indicators of Survival in Patients with Head and Neck Squamous Cell Carcinomas
por: Chang, Pei-Hung, et al.
Publicado: (2021)

Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer
por: Chang, Pei-Hung, et al.
Publicado: (2022)

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

A circulating miRNA signature for early diagnosis of acute kidney injury following acute myocardial infarction
por: Fan, Pei-Chun, et al.
Publicado: (2019)

Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer
por: Lee, Chun-Hui, et al.
Publicado: (2019)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Enhancing Prediction Performance by Add-On Combining Circulating Tumor Cell Count, CD45(neg) EpCAM(neg) Cell Count on Colorectal Cancer, Advance, and Metastasis
por: Chiu, Sherry Yueh-Hsia, et al.
Publicado: (2021)

Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer
por: Huang, Chi-Cheng, et al.
Publicado: (2023)

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
por: Wu, Chiao-En, et al.
Publicado: (2022)

Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients
por: Hung, Ming-Szu, et al.
Publicado: (2019)

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
por: Liao, Bin-Chi, et al.
Publicado: (2020)

The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors
por: Hsieh, Jason Chia-Hsun, et al.
Publicado: (2019)

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
por: Chang, John Wen-Cheng, et al.
Publicado: (2022)

The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Sensitive and Specific Biomimetic Lipid Coated Microfluidics to Isolate Viable Circulating Tumor Cells and Microemboli for Cancer Detection
por: Chen, Jia-Yang, et al.
Publicado: (2016)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Development of a Microfluidic-Based Optical Sensing Device for Label-Free Detection of Circulating Tumor Cells (CTCs) Through Their Lactic Acid Metabolism
por: Chiu, Tzu-Keng, et al.
Publicado: (2015)

Circulating Cell-Free DNA Levels Could Predict Oncological Outcomes of Patients Undergoing Esophagectomy for Esophageal Squamous Cell Carcinoma
por: Hsieh, Chih-Cheng, et al.
Publicado: (2016)

Cognitive impairment and its association with circulating biomarkers in patients with acute decompensated heart failure
por: Tung, Ying-Chang, et al.
Publicado: (2022)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
por: Lee, Suey-Haur, et al.
Publicado: (2022)

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
por: Hsu, Ping-Chih, et al.
Publicado: (2022)

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations
por: Liu, Chien-Ying, et al.
Publicado: (2017)

Circulating epithelial cell counts for monitoring the therapeutic outcome of patients with papillary thyroid carcinoma
por: Tseng, Ching-Ping, et al.
Publicado: (2017)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
por: Wu, Chih‐Hsun, et al.
Publicado: (2019)

Perfusion-diffusion Mismatch Predicts Early Neurological Deterioration in Anterior Circulation Infarction without Thrombolysis
por: Hsu, Chia-Yu, et al.
Publicado: (2015)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Polycarboxybetaine-Based Hydrogels for the Capture and Release of Circulating Tumor Cells
por: Chien, Hsiu-Wen, et al.
Publicado: (2022)

Circulating Endothelial-Derived Activated Microparticle: A Useful Biomarker for Predicting One-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer
por: Wang, Chin-Chou, et al.
Publicado: (2014)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pmujqq40nnpf31iherdof265ge